Work

Conventional and Pretargeted Radioimmunotherapy with Bismuth-213 to Target and Treat CD20-Expressing Non-Hodgkin Lymphoma: A Preclinical Model for Consolidation Therapy to Eradicate Minimal Residual Disease.

Year: 2009

Type: article

Source: Blood

DOI: 10.1182/blood.v114.22.2705.2705

Authors: Steven I. Park, Jaideep Shenoi, John M. Pagel, Donald K. Hamlin, Nural Orgun, Aimee L. Kenoyer, Shani M. Wilbur, Amanda Axtman, D. Scott Wilbur, Yukang Lin, Darrell R. Fisher, Ajay K. Gopal, Damian J. Green, Oliver W. Press

Institutions: University of Washington, Fred Hutch Cancer Center, Pacific Northwest National Laboratory

Language: English

Topic: Radiopharmaceutical Chemistry and Applications

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2574775448

FWCI:

Cites:

Cited by: 1

Related to: 10